Moderna Shares at a Crossroads: Scientific Support Meets Political Turbulence

After an extended period of decline, Moderna's stock is exhibiting signs of renewed investor interest. The recent uptick, however, highlights a fundamental clash between encouraging scientific data and a shifting, uncertain political landscape in a key market.

To navigate current challenges, Moderna has taken decisive steps to fortify its financial position. In late November, the company secured a $1.5 billion credit facility, aimed at ensuring operational stability. Management projects total liquidity will reach between $7.1 and $7.6 billion in 2025. This bolstering of the balance sheet comes as revenue for the third quarter fell 45.4% year-over-year to $1.02 billion, reflecting the sharp decline in respiratory vaccine sales.

The recent share price movement—a gain of approximately 14% in one week to around €23.80—appears fueled largely by speculative trading. Market data indicates a significant surge in call option volume, pointing to short-term bets on a continued recovery. Institutional sentiment, however, remains divided. While Norway's sovereign wealth fund, Norges Bank, established a new substantial position valued at nearly $95 million, the New York State Common Retirement Fund nearly halved its stake during the second quarter of 2025.

A Study Provides Tailwinds, While U.S. Policy Shifts Create Headwinds

The immediate catalyst for increased market attention is a French long-term study published in JAMA Network Open. The research found a 74% to 75% lower mortality risk among vaccinated individuals and no evidence of increased long-term mortality. These findings offer crucial scientific validation for the core mRNA technology.

Should investors sell immediately? Or is it worth buying Moderna?

Simultaneously, political risks in the United States have intensified considerably. The appointment of Robert F. Kennedy Jr. as Secretary of Health and Human Services has created substantial uncertainty. Reports suggest that up to $500 million in government research funding for mRNA projects could be cut. Furthermore, critics of current vaccine recommendations are gaining a more prominent platform within advisory committees at the U.S. Centers for Disease Control and Prevention (CDC).

Strategic Pivot Toward Oncology as Analysts Remain Cautious

With revenue from its respiratory vaccines waning, Moderna's strategic focus is now squarely on diversification. The company is aggressively redirecting resources into oncology, with the recently secured financing intended to bridge the gap until these new therapies can potentially be commercialized.

Market experts continue to express caution. The average analyst price target stands at about €29.50, coupled with a prevailing "Reduce" rating, suggesting limited near-term upside potential is expected.

The equity now finds itself at a pivotal juncture. The assured liquidity and positive study data may establish a temporary floor for the share price. Nevertheless, the overarching trend continues to be weighed down by political uncertainties and the diminishing demand for COVID-19 vaccines. Forthcoming quarterly results and further developments in U.S. health policy will likely dictate the stock's next sustained move.